BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

CoLucid Pharmaceuticals, Inc. 

902 North Capitol Avenue
Suite 302
Indianapolis  Indiana  46204  U.S.A.
Phone: 317-684-6703 Fax:


SEARCH JOBS




Industry
Pharmaceutical






 Company News
CoLucid Pharmaceuticals, Inc. and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine 10/23/2013 9:51:59 AM    More...
CoLucid Pharmaceuticals, Inc. Release: New Study Results Regarding Cardiovascular Contraindications to Triptans in the Migraine Population to be Presented at the 16th Congress of the International Headache Society, June 30, in Boston, MA 6/27/2013 6:44:19 AM    More...
CoLucid Pharmaceuticals, Inc. Release: New Study Shows That Majority of Acute Migraine Patients Have Cardiovascular Disease Risk Factors and One Third Have Cardiovascular Disease 12/21/2012 8:22:50 AM    More...
CoLucid Pharmaceuticals, Inc. to Attend the BIO-Europe 2012 Meeting in Hamburg, Germany 11/8/2012 10:03:01 AM    More...
CoLucid Pharmaceuticals, Inc. Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy 9/18/2012 10:29:01 AM    More...
CoLucid Pharmaceuticals, Inc. Founder Passes Away 2/8/2012 6:49:13 AM    More...
CoLucid Pharmaceuticals, Inc. to Present at the Biotech Showcase During J.P. Morgan Healthcare Conference 1/4/2012 1:31:25 PM    More...
CoLucid Pharmaceuticals, Inc. to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan 9/29/2011 11:51:10 AM    More...
CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks 6/9/2010 11:06:50 AM    More...
CoLucid Pharmaceuticals, Inc. to Present at the Oppenheimer 20th Annual Healthcare Conference on November 3, 2009 10/27/2009 9:49:17 AM    More...
12